Back to Search
Start Over
Examination of the PET in vivo generator 134Ce as a theranostic match for 225Ac.
- Source :
- European Journal of Nuclear Medicine & Molecular Imaging; Nov2024, Vol. 51 Issue 13, p4015-4025, 11p
- Publication Year :
- 2024
-
Abstract
- Purpose: The radionuclide pair cerium-134/lanthanum-134 (<superscript>134</superscript>Ce/<superscript>134</superscript>La) was recently proposed as a suitable diagnostic counterpart for the therapeutic alpha-emitter actinium-225 (<superscript>225</superscript>Ac). The unique properties of <superscript>134</superscript>Ce offer perspectives for developing innovative in vivo investigations that are not possible with <superscript>225</superscript>Ac. In this work, <superscript>225</superscript>Ac- and <superscript>134</superscript>Ce-labelled tracers were directly compared using internalizing and slow-internalizing cancer models to evaluate their in vivo comparability, progeny meandering, and potential as a matched theranostic pair for clinical translation. Despite being an excellent chemical match, <superscript>134</superscript>Ce/<superscript>134</superscript>La has limitations to the setting of quantitative positron emission tomography imaging. Methods: The precursor PSMA-617 and a macropa-based tetrazine-conjugate (mcp-PEG<subscript>8</subscript>-Tz) were radiolabelled with <superscript>225</superscript>Ac or <superscript>134</superscript>Ce and compared in vitro and in vivo using standard (radio)chemical methods. Employing biodistribution studies and positron emission tomography (PET) imaging in athymic nude mice, the radiolabelled PSMA-617 tracers were evaluated in a PC3/PIP (PC3 engineered to express a high level of prostate-specific membrane antigen) prostate cancer mouse model. The <superscript>225</superscript>Ac and <superscript>134</superscript>Ce-labelled mcp-PEG<subscript>8</subscript>-Tz were investigated in a BxPC-3 pancreatic tumour model harnessing the pretargeting strategy based on a trans-cyclooctene-modified 5B1 monoclonal antibody. Results: In vitro and in vivo studies with both <superscript>225</superscript>Ac and <superscript>134</superscript>Ce-labelled tracers led to comparable results, confirming the matching pharmacokinetics of this theranostic pair. However, PET imaging of the <superscript>134</superscript>Ce-labelled precursors indicated that quantification is highly dependent on tracer internalization due to the redistribution of <superscript>134</superscript>Ce's PET-compatible daughter <superscript>134</superscript>La. Consequently, radiotracers based on internalizing vectors like PSMA-617 are suited for this theranostic pair, while slow-internalizing <superscript>225</superscript>Ac-labelled tracers are not quantitatively represented by <superscript>134</superscript>Ce PET imaging. Conclusion: When employing slow-internalizing vectors, <superscript>134</superscript>Ce might not be an ideal match for <superscript>225</superscript>Ac due to the underestimation of tumour uptake caused by the in vivo redistribution of <superscript>134</superscript>La. However, this same characteristic makes it possible to estimate the redistribution of <superscript>225</superscript>Ac's progeny noninvasively. In future studies, this unique PET in vivo generator will further be harnessed to study tracer internalization, trafficking of receptors, and the progression of the tumour microenvironment. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 16197070
- Volume :
- 51
- Issue :
- 13
- Database :
- Complementary Index
- Journal :
- European Journal of Nuclear Medicine & Molecular Imaging
- Publication Type :
- Academic Journal
- Accession number :
- 180627526
- Full Text :
- https://doi.org/10.1007/s00259-024-06811-w